Navigation Links
Boehringer Ingelheim and Ashoka Changemakers Launch Competition to Find Business Models that Transform Health Systems

WASHINGTON and INGELHEIM, Germany, Jan. 24, 2013 /PRNewswire-USNewswire/ -- Boehringer Ingelheim and Ashoka Changemakers are launching Transforming Health Systems: Gamechanging Business Models, an online competition to discover innovative business models that are solving critical problems in health systems around the world.

"Traditional healthcare systems in mature markets are not designed to encourage enough collaboration between key players, such as care providers, insurance companies, and government organizations," said Jean Scheftsik de  Szolnok, Vice-President Southern Europe for Boehringer Ingelheim and Making More Health Steering Committee Chair. "Often, the systems' misaligned incentives fail to produce real value for patients and society. Innovative business models are urgently needed to solve this issue."

Transforming Health Systems also seeks business models that confront problems in emerging markets where governments, businesses, and non-profits often lack the resources or commitment to serve communities in need.

Winners will receive awards totaling US $85,000 plus support from Boehringer Ingelheim to help advance their business models. They will be matched with Boehringer Ingelheim's local country offices, and will be able to explore the potential for partnerships or further on-going support. All individuals, organizations, or partnerships are eligible to enter from now until April 10, 2013 at

Transforming Health Systems was built on key insights gained from the first Making More Health competition launched by Boehringer Ingelheim and Ashoka Changemakers.

"The previous Making More Health competition added tremendously to Ashoka's network of social entrepreneurs who are working to solve the critical problems plaguing the world's health systems," said Ashoka President Diana Wells . "We have found that in tackling health from a systems level, most of our social entrepreneurs are finding ways to 1) deliver unlikely allies to solve the healthcare practitioner shortage  or 2) are innovating new delivery systems which can reach low income populations in both urban and rural areas.  We are excited to partner with Boehringer Ingelheim once again to tap the transformative power of social entrepreneurship and to solve one of the most critical issues that is confronting society today."

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing, and marketing novel products of high therapeutic value for human and veterinary medicine.

Social responsibility is a core element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of its global operations. Mutual cooperation and respect, as well as environmental protection and sustainability, are intrinsic values of all of Boehringer Ingelheim's endeavors.

For more information please visit

About Ashoka Changemakers

Ashoka Changemakers is a community of action that connects social entrepreneurs around the globe to share ideas, inspire, and mentor each other. Through its online collaborative competitions and open-source process, is one of the world's most robust spaces for launching, discussing, and funding ideas to solve the world's most pressing social problems. Changemakers builds on Ashoka's three-decade history and belief that we all have the ability to be a Changemaker.

Media Contact:
Sonia Bianchi
Media Manager, Ashoka Changemakers 

SOURCE Ashoka Changemakers
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
(Date:11/27/2015)... 2015  Lannett Company, Inc. (NYSE: LCI ... acquisition of Kremers Urban Pharmaceuticals Inc. (KU), the ... company UCB S.A. (Euronext: UCB). ... KU from UCB for total consideration of approximately ... customary working capital adjustment, a deduction of certain ...
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... Un nuevo enfoque combina la ... cáncer avanzado.   --> Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... --> Clinical Cancer Research . --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... An inventor, from Hopkinsville, Ky., thought there ... home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. provides ... so, it could help to prevent potential overdose situations. As a result, it ...
(Date:11/27/2015)... Aliso Viejo, CA (PRWEB) , ... November 27, 2015 , ... ... exclusively for use in Final Cut Pro X. With ProSidebar: Fasion, video editors ... banners, or use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television ... an interesting show that delves into an array of issues that are presently affecting ... benefit from open dialogue, this show is changing the subjects consumers focus on, one ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
Breaking Medicine News(10 mins):